



BioPharmica Limited

11 September 2006

ASX
Company Announcements Office

ASX Announcement – BioPharmica (ASX: BPH)

BPH secures “ Tumour Suppressor Factor” Patent number 784629

BioPharmica is pleased to announce that its HLS5 cancer gene project undertaken with the University of Western Australia and WAIMR has been granted a new Australian patent entitled Tumour Suppressor Factor.

BioPharmica is working with Professor Klinken and his group in the Western Australian Institute for Medical Research (WAIMR) to commercialise the molecular marker for early and accurate cancer detection and treatment. Results released in 2006 show that HLS5 has a role in the regulation of gene expression and thus a role in the development of diseases such as cancer, Huntington's disease and AIDS.

A pre-clinical trial was previously conducted at the Royal Perth Hospital campus of WAIMR involving a 70-sample study of the HLS5 cancer marker in normal tissues and confirmed cancers (breast, prostate, lung and colon), as well as a panel of cancer cell lines.

- The pre-clinical trial was an outstanding success with WAIMR scientists directly correlating the presence of a fault in the HLS5 gene and the development of cancer in humans.
- Results showed that over 50% of patients with particular types of cancer had a fault in their HLS5 gene.
- Scientists were also able to determine the specific types of cancer in which the HLS5 gene fault occurs.
- A very sensitive test for detecting the HLS5 cancer gene marker was developed and used in the pre-clinical trial.

BioPharmica has been concentrating on the protection of the HLS5 intellectual property. The patent enables BioPharmica to move the HLS5 project further through the commercialisation process.

BioPharmica has exclusive rights to the tumor suppressor gene 'HLS5' and its associated pathway.

In recognition of its potential in detecting and treating cancer; HLS5 has attracted over \$1M in research funding from the NHMRC, Cancer Council of WA, the National Breast Cancer Foundation and the Medical Research Foundation of Royal Perth Hospital.

Further Provisional patents have been filed concerning HLS5 and its associated pathways. More information will become available as the IP strategy is implemented.

Yours sincerely,

DAVID BREEZE
DIRECTOR